COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies

  title={COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies},
  author={Renuka Raman and K. J. Patel and Kishu Ranjan},
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of the coronavirus disease 2019 (COVID-19) pandemic, which has been a topic of major concern for global human health. The challenge to restrain the COVID-19 pandemic is further compounded by the emergence of several SARS-CoV-2 variants viz. B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma) and B.1.617.2 (Delta), which show increased transmissibility and resistance towards vaccines and therapies. Importantly, there… 

Figures and Tables from this paper

SARS-CoV-2 Variants, Vaccines, and Host Immunity
Both SARS-CoV-2-induced host immune activation and vaccine-induced immune responses are reviewed, highlighting the responses of immune memory cells that are key indicators of host immunity.
Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines
The potential risk of the newly classified Mu variant of interest, seeming a highly vaccine-resistant variant, and the approaches that can be adopted to tackle this variant based on the available evidence are discussed.
Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants
Five compounds identified and validated have antiviral activity against ancestral SARS-CoV-2 and emerging variants from South Africa and Scotland, and MU-UNMC-2 displayed high synergy with remdesivir, the only approved drug for treating hospitalized COVID-19 patients.
Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant
The Omicron variant evades the protection rendered by vaccine-induced antibodies and natural infection, as well as overpowers the antibody-based immunotherapies, raising the concerns of current effectiveness of available vaccines and monoclonal antibody- based therapies.
Consecutive Hits of COVID-19 in India: The Mystery of Plummeting Cases and Current Scenario.
Recently, increased surveillance and monitoring, strengthening of medical facilities, campaigns of awareness programs, progressive vaccination drive, and high collaborative efforts have led to limiting the surge of COVID-19 cases in India to a low level.
What Happens to the Immune System after Vaccination or Recovery from COVID-19?
The way in which the immune system responds to a SARS-CoV-2 infection is detailed, including innate and adaptive measures, and the role of vaccination, the main types of COVID-19 vaccines and how they protect us are described.
TB and COVID-19: An Exploration of the Characteristics and Resulting Complications of Co-infection
A literature review focuses on the pathogenicity of SARS-CoV-2 infection with both latent and active TB, as well as the challenges in treating TB during the COVID-19 pandemic, and explores the biomolecular effects of these contributors to pathogenicicity of both diseases.


The trinity of COVID-19: immunity, inflammation and intervention
The interaction of SARS-CoV-2 with the immune system and the subsequent contribution of dysfunctional immune responses to disease progression is described and the implications of these approaches for potential therapeutic interventions that target viral infection and/or immunoregulation are highlighted.
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
The data suggest that control of some emergent SARS-CoV-2 variants may benefit from updated vaccines, including the Gamaleya Sputnik V Ad26 / Ad5 vaccine.
Monoclonal Antibodies for Prevention and Treatment of COVID-19.
The coronavirus disease 2019 (COVID-19) pandemic has created a worldwide crisis and inspired an urgent search for prevention and treatment of severe acute respiratory syndrome coronavirus 2
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
It is shown that the adenovirus-vector-based vaccine ChAdOx1 nCoV-19, which encodes the spike protein of SARS- CoV-2, is immunogenic in mice and elicites a robust humoral and cell-mediated response.
SARS-CoV-2 vaccines in development
The development of vaccines against SARS-CoV-2 is reviewed, including an overview of the development process, the different types of vaccine candidate, and data from animal studies as well as phase I and II clinical trials in humans.
Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage, and new variants with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines.
SARS-CoV-2 Vaccines: Status Report
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B. 1.1.351 variant, and this variant showed greater resistance to the pseudovirus and the live-virus neutralization assays than in samples from placebo recipients.
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development